Muscarinic acetylcholine receptor (M3)

Class

short-acting muscarinic antagonist (SAMA) / anticholinergic bronchodilator — oxitropium bromide, Boehringer Ingelheim compound Ba253, delivered via BINEB nebulizer

Pathway

blocks acetylcholine-mediated airway smooth-muscle contraction

The M3 muscarinic acetylcholine receptor is a G-protein-coupled receptor expressed on airway smooth muscle, submucosal glands, and other tissues. In the lungs, the neurotransmitter acetylcholine, released from vagal nerve endings, binds M3 receptors to trigger smooth-muscle contraction and mucus secretion. This cholinergic tone is a major contributor to airway narrowing in chronic obstructive pulmonary disease (COPD) and, to a lesser degree, asthma. Blocking M3 with an antagonist ('anticholinergic' or antimuscarinic agent) prevents acetylcholine from activating this contractile pathway, producing bronchodilation and reduced mucus output. Because acetylcholine also acts on a related subtype, M2, which normally provides negative feedback on its own release, effective bronchodilators are designed to act preferentially at M3 over M2 so as not to blunt this self-limiting mechanism. Antimuscarinic bronchodilators fall into short-acting and long-acting classes, distinguished largely by how quickly the drug dissociates from the receptor once bound; short-acting agents wash out relatively quickly, while long-acting ones remain bound for many hours, allowing once- or twice-daily dosing. This mechanism broadly matters wherever cholinergic-driven bronchoconstriction is a dominant feature of airway disease, and it complements other bronchodilator classes such as beta-agonists, which act through a distinct signaling pathway.